Skip to main content

Table 4 COPD exacerbations, prior to and during the study (per protocol set)

From: Impact of switching from triple therapy to dual bronchodilation in COPD: the DACCORD ‘real world’ study

 

LABA/LAMA FDC (N = 292)

Triple therapy (N = 675)

During the 12 months prior to baseline

  

Patients with ≥ 1 COPD exacerbation, n (%)

127 (43.5)

330 (48.9)

 p value

0.123

Number of exacerbations, n (%)

  

 0

165 (56.5)

345 (51.1)

 1

108 (37.0)

214 (31.7)

 2

19 (6.5)

81 (12.0)

  ≥ 3

0 (0.0)

35 (5.2)

During the study

  

Patients with ≥ 1 COPD exacerbation, n (%)

54 (18.5)

194 (28.7)

 p value

 < 0.001

Number of exacerbations, n (%)

  

 0

238 (81.5)

481 (71.3)

 1

45 (15.4)

127 (18.8)

 2

9 (3.1)

43 (6.4)

  ≥ 3

0 (0.0)

24 (3.6)

Annualised exacerbation rate during the study (95% confidence limit)

0.212 (0.164, 0.274)

0.436 (0.375, 0.507)

  1. COPD chronic obstructive pulmonary disease, LABA long-acting β2-agonist, LAMA long-acting muscarinic antagonist, FDC fixed-dose combination